Sign In
Buy ITCI
$131.87
+0 (+0%)
At Close: Jul 01, 2025
Intra-Cellular Therapies Reports Third Quarter 2022 Financial Results and Provides Corporate Update
11:30am, Thursday, 03'rd Nov 2022 GlobeNewswire Inc.
CAPLYTA net product revenues for the third quarter 2022 were $71.9 million, compared to $21.6 million for the same period in 2021, representing a 233% increase over the same period in 2021 and a 30%
Intra-Cellular Therapies (ITCI) Reports Q3 Loss, Tops Revenue Estimates
10:34am, Thursday, 03'rd Nov 2022
Intra-Cellular (ITCI) delivered earnings and revenue surprises of 33.72% and 10.66%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Intra-Cellular Therapies to Host Third Quarter 2022 Financial Results Conference Call and Webcast
12:00pm, Thursday, 27'th Oct 2022 GlobeNewswire Inc.
NEW YORK, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central n
Here's Why You Should Add Intra-Cellular Therapeutics (ITCI) Stock Now
02:43pm, Monday, 17'th Oct 2022 Zacks Investment Research
Intra-Cellular's (ITCI) product revenues are primarily driven by higher sales of its schizophrenia and bipolar disorder drug Caplyta. Caplyta is also being evaluated for other CNS indications.
Here's Why You Should Add Intra-Cellular Therapeutics (ITCI) Stock Now
12:03pm, Monday, 17'th Oct 2022
Intra-Cellular's (ITCI) product revenues are primarily driven by higher sales of its schizophrenia and bipolar disorder drug Caplyta. Caplyta is also being evaluated for other CNS indications.
Intra-Cellular Therapies: What Lies Ahead
07:45pm, Tuesday, 20'th Sep 2022
Today, we circle back on mid-cap biopharma name Intra-Cellular Therapies, Inc. for the first time since 2020. Intra-Cellular Therapies' flagship product CAPLYTA (lumateperone) has significant potentia
Benzinga's Top Ratings Upgrades, Downgrades For August 22, 2022
02:03pm, Monday, 22'nd Aug 2022 Benzinga
Upgrades
William Blair upgraded the previous rating for Foot Locker Inc (NYSE:FL) from Sell to Hold. For the second quarter, Foot Locker had an EPS of $1.10, compared to year-ago quarter EPS of $2.21.
Illumina, Poshmark, Olo And Some Other Big Losers From Friday
09:17am, Monday, 15'th Aug 2022 Benzinga
U.S. stocks closed higher on Friday, with the Dow Jones gaining more than 400 points. Here is the list of some big stocks moving lower in the previous session.
CS Disco, Inc. (NYSE: LAW) shares fell
Where Intra-Cellular Therapies Stands With Analysts
07:26pm, Thursday, 11'th Aug 2022 Benzinga
Within the last quarter, Intra-Cellular Therapies (NASDAQ:ITCI) has observed the following analyst ratings:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
4
1
0
Intra-Cellular Therapies, Inc. (ITCI) CEO Sharon Mates on Q2 2022 Results - Earnings Call Transcript
02:25pm, Tuesday, 09'th Aug 2022
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI ) Q2 2022 Earnings Conference Call August 9, 2022 8:30 AM ET Company Participants Juan Sanchez - Vice President, Corporate Communications and Investor Relat
Intra-Cellular Therapies (ITCI) Reports Q2 Loss, Tops Revenue Estimates
12:45pm, Tuesday, 09'th Aug 2022 Zacks Investment Research
Intra-Cellular (ITCI) delivered earnings and revenue surprises of -16.46% and 12.93%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Intra-Cellular Therapies Reports Second Quarter 2022 Financial Results and Provides Corporate Update
11:30am, Tuesday, 09'th Aug 2022 GlobeNewswire Inc.
Total revenues for the second quarter 2022 were $55.6 million, compared to $20.0 million for the same period in 2021, representing a 178% increase
Is a Surprise Coming for Intra-Cellular (ITCI) This Earnings Season?
02:16pm, Monday, 08'th Aug 2022 Zacks Investment Research
Intra-Cellular (ITCI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Arbutus Biopharma (ABUS) Reports Q2 Loss, Tops Revenue Estimates
01:05pm, Thursday, 04'th Aug 2022 Zacks Investment Research
Arbutus (ABUS) delivered earnings and revenue surprises of 23.08% and 165.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Lags Revenue Estimates
12:25pm, Tuesday, 02'nd Aug 2022 Zacks Investment Research
Rhythm Pharmaceuticals, Inc. (RYTM) delivered earnings and revenue surprises of -12.66% and 58.13%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the
